We propose that such combined therapy might be efficient in eliminating TKI-resistant primary CML cells with hyperactivated STAT5, often leading to BCR-ABL1-independent resistance. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.